Mutations in the Fas (apo-1, CD95) gene result in autoimmune lymphoproliferative syndrome (ALPS).
Introduction
Autoimmune lymphoproliferative syndrome (ALPS) (MIM 601859) is a disease of lymphocyte homeostasis, T cells from ALPS patients demonstrate a resistance to apoptosis compared with T cells from healthy subjects. Patients also demonstrate enlargement of the spleen and lymph nodes, excessive numbers of double negative (CD4 − CD8 − ) T cells and a variety of autoimmune manifestations. 1 Most patients with ALPS possess a genetic mutation within the Fas gene (Apo-1, CD95, TNFRSF6) and are designated as ALPS type 1a (mutations in other genes give rise to ALPS types 1b, 2 and 3).
Fas, is a cell surface, transmembrane signalling protein of approximately 48 kDa, which plays a key role in mediating programmed cell death (apoptosis). It is expressed at high levels on thymocytes at the double positive (CD4 + , CD8 + ) stage, and also on activated peripheral T and B cells. Mutations in the gene, located at chromosome 10p24.1 in humans, can cause lymphoproliferative disease and systemic lupus erythematosus like autoimmunity. 2, 3 The majority of defects in humans are found within exons 7-9 which encode the intracellular domain of Fas, and are predominantly small deletions and mis-and nonsense mutations. Alternatively, splice site mutations may cause loss of exons. Further studies demonstrated that mutations in the intracellular death domain of Fas had dominant negative effects. 4, 5 The mutant forms of Fas complexed with wild-type Fas are less effective in their interaction with intracellular signalling protein FADD/MORT1 and this is the basis of the defect in apoptosis. 6, 7 In our studies, two patients, a father and son, presented with clinical features of ALPS and were investigated to determine the nature of any likely mutation. Initially these patients were examined for defects in the Fas gene, as it represents the most prevalent type of ALPS defect.
Results

In vitro apoptosis studies
Functional analysis of Fas-mediated apoptosis in the patients peripheral blood lymphocytes revealed resistance to apoptosis (5% Ϯ 5% compared to 90% Ϯ 8% for controls; see Figure 1 ), a characteristic of ALPS sufferers. region with primers F3 and R2 (results not shown). Direct sequencing of the PCR products failed to resolve at the region corresponding to exon 8 which lead us to subclone the PCR products for further analysis. Sequencing of the clones revealed a 1:1 ratio of the correct Fas sequence at the position of exon 8 and a splice variant where exon 8 was absent. Such splice variants have been reported previously and can be caused by a variety of different mutations, usually within the donor and acceptor splice sites of exon 8, so the genomic DNA was examined to determine the nature of the causative defect.
Genomic analysis
Amplification of a larger region from exon 7 to 9 produced two PCR products, one of 2143 bp as expected, and one being approximately 330+ bp larger than expected. (Figure 2a ). Restriction digestion of these two products with Dra I provided the expected pattern of fragments, and one additional 748-bp fragment not seen in normal controls (Figure 2b) . Purification of the larger PCR product and digestion with Dra I revealed the presence of the 748-bp fragment and loss of the expected 417-bp fragment, which encompasses exon 8. This 748-bp Dra I fragment was subcloned into pNEB193 and sequenced. This revealed the presence of a 331-bp insertion into intron 7, 50 bp 5′ of exon 8. The insertion is shown schematically in Figure 2c .
The sequence is shown in Figure 3 and analysis using Genbank and repeatermask revealed it to be an inserted Alu element, composed of a 281-bp Alu repeat element with a 34-base polyA tract and 17 base perfect direct repeats flanking the inserted element. The insertion best matches the Alu -Sb1 SINE consensus sequence (accession number HSU14569) identity with the insert is 99.31% (286/288 bp) with a single gap (0.35%;1/289 bp). This Alu element is inserted in the antisense direction relative to the Fas gene.
Genes and Immunity
Discussion
Mutations in the Fas (CD95) gene give rise to disorders of lymphocyte homeostasis and autoimmunity. The first reported mutations in Fas were found in the lymphoproliferative (lpr) mouse. 8 Two mutations exist, lpr and lpr cg . The lpr cg mutation, unlike the lpr mutation shows partial non-allelic non-complementation with the gld (Fas ligand) mutant mouse. 9 The defect in the lpr mouse is due to the insertion of an early transposable element (ETn) retrotransposon into intron 2 of the Fas gene. This insertion results in the production of truncated Fas mRNAs containing only exons 1 and 2, whilst lpr cg is the result of a point mutation resulting in a change of IleϾAsp within the cytoplasmic (signalling) domain, and abolition of signal transduction via the receptor. 10 The lpr cg mouse is therefore analogous to the point mutations thus far reported in ALPS patients.
We report here the discovery of a novel mutation in the Fas gene that leads to autoimmune lymphoproliferative syndrome. The defect is the result of a de novo Alu element insertion into intron 7 of the Fas gene, approximately 50 bp upstream of exon 8. The mutation does not directly disrupt the donor or acceptor splice junctions of exon 8 but does affect splicing in some way, leading to the production of an alternatively spliced mRNA where exon 8 is absent. This results in a truncated Fas protein and a defect in its ability to signal. Truncation of this protein, has been reported before in ALPS patients with a similar phenotype, but truncation is usually the result of a mutation in the splice junctions of exon 8. Alu sequences are commonly found within the human genome, representing around 6-13% of the total genomic DNA. They are thought to be retrotransposons, and newly retrotransposed Alu elements are flanked by perfect direct repeats of host sequence, consistent with insertion into staggered nicks in the target DNA.
11 This is consistent with the insert within the patients examined in this study, which contain flanking perfect direct repeats (see Figure 3) . Overall it has been estimated that Alu insertion may account for approximately 0.1% of known human genetic diseases and that the majority of disease causing insertions are into coding regions disrupting the reading frame directly, or into introns but close to an exon, where splicing is affected. 12 Alu elements can have strong effects on gene expression when present within introns, especially when inserted in the antisense direction. They can alter normal splicing patterns for a gene or cause cryptic splice donor or acceptor sites and resultant abnormal protein. In this case, the resultant loss of an exon is similar to that reported for Alu element insertion in neurofibromatosis type 1.
13
Analysis of the locations and types of mutations found within the Fas gene to date indicate that approximately 70% of mutations occur in exons 7 to 9 of the gene, which encode the intracellular death domain of the protein. The penetrance of ALPS phenotype is far greater in these mutations than in those in the extracellular domains of Fas. 4 The disruption of Fas by a retrotransposon inserting into an intron is therefore similar to, and the first reported example of, a human analogue of the lpr mouse ETn mutation. However it must be recognised that the disruption in the lpr mouse is within the second intron and is required in the homozygous form to become manifest, whereas the mutation we report provides a pheno- (a) Electrophoresis of exon-7-9 PCR product from control normal sample (C) and patient 1 (P1; both patients showed identical patterns, and patient 2 is not shown) P1 shows both the expected 2143 bp product and a larger 2475 bp product (arrowed). (b) This larger PCR product is further analysed by restriction digestion. Both the expected product and the larger product were subjected to digestion with restriction endonuclease Dra 1: C-control Fas exon 7-9 PCR product; P1 patient 1 PCR products (unseparated); UB -2475 bp product from P1; LB -2143 product from P1. Both P1 and UB show the 748 bp Dra1 fragment generated from the larger PCR product (arrowed for UB). Lane UB also shows the loss of the expected 417 bp fragment. All digests showed the 169 bp band (not visible in this image). (c) Diagrammatic representation of the exon 7-9 PCR products analysed in parts a and b. The white bar represents the entire 2143 bp of the PCR product, the length in bp indicated above it. The black segment represents exon 8 and the grey insert the additional 331 bp found within the 748 bp Dra1 fragment. Dra1 fragment sizes for the control (normal) PCR product are indicated in brackets, and the Dra1 cut sites with arrows. The insert lies within the 417 bp Dra1 fragment. type identical to that seen for other mutations affecting the signalling domain of Fas (ie, is dominant negative). Despite this difference, there are now examples in both humans and mice of signalling domain point mutations or ETn disruption of splicing affecting the same gene. This report represents the first example of Alu retrotransposition within the Fas gene that results in ALPS, and perhaps further highlights the 'mutational hotspot' nature of this region of the Fas gene.
Materials and methods
Clinical
A 22-month-old boy was referred because of generalised lymphadenopathy, splenomegaly and associated febrile episodes. Symptoms had been noted since 4 months of age and had initially been thought due to toxocariasis, however treatment with thiabendazole produced no improvement. Infectious, inflammatory and malignant causes were considered and investigative results were as follows. Serological investigations were negative for: Adenovirus, Bartonella species, CMV, Epstein-Barr virus, herpes simplex, herpes zoster, HIV, Influenza A and B, measles, mumps, mycoplasma pneumoniae, rubella, parvovirus and Q fever. /L (0.7-1.3), CD16/56 0.44 (0.2-0.6). There was normal in vitro lymphocyte proliferation to PHA and PMA, T cell gene rearrangement pattern and interferon gamma receptor expression. Lymph node biopsy showed no evidence of lymphoma, Hodgkin's disease or granulomatous processes. Bone marrow examination was normal. It was noted that the boy's 26-year-old father had mild to moderate lymphadenopathy over the previous 15 years. A lymph node biopsy on the father 3 years previously had shown only reactive changes. The parasitology reference laboratory subsequently issued a revised serological report, indicating that toxocara serology was negative on re-testing with an improved assay. A presumptive diagnosis of histiocytosis Class II syndrome (sinus histiocytosis with massive lymphadenopathy/Rosai Dorfman disease) was made, and review of the histopathology supported that diagnosis with strong S100 staining. As this condition is considered clinically benign, the child's progress was initially monitored and specific treatment was not introduced. A second expert opinion was sought regarding the lymph node histology of the boy, and also of an earlier biopsy from his father. A diagnosis of ALPS was made on both biopsies, confirmed by the finding of CD4 −
CD8
− infiltrates. He was commenced on oral prednisolone therapy (25 mg daily) to control lymphadenopathy and fever, with good effect. CT scans had previously confirmed enlarged lymph nodes at the root of the neck, both supraclavicular fossae and axillae, the superior mediastinum, pre and subcarinal regions, within small bowel mesentery and alongside the iliac vessels.
Functional Fas assay
Anti-CD95 monoclonal-induced T lymphocyte apoptosis was measured as previously. 2 Peripheral blood mononuclear cells (PBMC) were activated for 8 days with PHA and IL-2 (Genzyme, 20 IU/ml), then cultured with Apo-1 monoclonal ab (250 ng/ml) and a rat anti-mouse IgG (Jackson Laboratories, Westgrove, USA,10 g/ml) for 24 h. Apoptotic cells were quantified by resuspending cells in a hypotonic solution containing 0.1% sodium citrate, Genes and Immunity 0.1% Triton X-100 (Sigma, St Louis, MO, USA) and 50 g/ml propidium iodide (Sigma). Red fluorescence was measured using a FACStar plus flow cytometer (Becton Dickinson, Oxford, UK). Apoptotic cells were counted as hypodiploid.
Molecular examination
Total RNA was isolated from peripheral blood using the Qiagen Rneasy kit and cDNA was produced using oligo-(dT) primed reverse transcription in Pharmacia (CA, USA) Ready-to-Go cDNA synthesis tubes following the manufacturers recommendations.
RT-PCR of the Fas sequence was performed using the primers described by Rieux-Laucat et al 2 (F2: TGCCAA-GAAGGGAAGGAGTA; F3: AGAAAGCACAGAAAG-GAAAACC; R1: ACTTTCTGTTCTGCTGTGTCTT; R2: ACAGCCAGCTATTAAGAATC). These primers amplify across the region of the Fas cDNA corresponding to the intracellular domain of the protein.
PCR products were cloned into pNEB193 (New England Biolabs (UK)). DNA sequencing of PCR products directly and also of cloned products, was performed on an ABI 310 fluorescent analyser, using Big-dye chemistries.
Genomic PCR was performed with a high fidelity Elongase polymerase mix (Life Technologies Ltd, Paisley, UK) using primers either flanking exon 8 closely, or from exon 7 to exon 9 of Fas. Primers were designed using the program Primer 3 (Whitehead Institute, MIT, USA) using genbank sequences Z47992 (Fas exons 5-7) and Z66557 (Fas exons 7-9) as our model. Primer sequences were: Fas ex8a: GGCCGGAACCTTTCAGAATA; Fas ex8b: TGCT TATGCTGAGCAGGTAGAA (product size 365bp); Fas Ex7: GGAAGTACAGAAAACATGCAGAAA; Fas ex9 : ATGACTCCAGCAATAGTGGTGATA (product size 2143). PCR was performed in 25-l volumes following manufacturers recommendations and the following cycles: 2 min at 94°C then 35 cycles of 94°C, 1 min; 56°C, 1 min; 72°C, 4 min. Followed by a final incubation of 72°C, 20 min.
Restriction Digests were performed using standard techniques on purified PCR products.
